Cybin launches strategic clinical site partnerships to support paradigm, a multinational pivotal phase 3 program evaluating cyb003 for the adjunctive treatment of major depressive disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the launch of its first strategic partnership agreement (“spa”) with segal trials in furtherance of cybin's multinational pivotal phase 3 program evaluating cyb003 for the adjunctive treatment of major de.
CYBN Ratings Summary
CYBN Quant Ranking